Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC9 | Q9Y397 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | IDE | P14735 | 2/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511977 | 1.00 | ZDHHC9 (1.00) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL20378484 | 1.00 | ZDHHC9 (1.00) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL26464591 | 0.94 | ZDHHC9 (0.90) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL20511973 | 0.89 | ZDHHC9 (1.00) | ZDHHC9L3MBTL1TDP1MAPTPAX8 | |
| SCHEMBL20378498 | 0.86 | ZDHHC9 (0.75) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL20378494 | 0.86 | ZDHHC9 (0.75) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL20511976 | 0.81 | ZDHHC9 (0.67) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL20378490 | 0.81 | ZDHHC9 (0.67) | ZDHHC9L3MBTL1MITFMEN1KMT2A | |
| SCHEMBL20511978 | 0.79 | ZDHHC9 (0.77) | ZDHHC9TDP1 | |
| SCHEMBL20511975 | 0.79 | ZDHHC9 (0.77) | ZDHHC9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135119-A1 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-04 | — | — | US | disclosed |
| US-20230135119-A1 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-04 | — | — | US | disclosed |
| US-20230135119-A1 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-04 | — | — | US | disclosed |
| US-10085981-B2 | Protein acyl transferase inhibitors and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180200250-A1 | PROTEIN ACYL TRANSFERASE INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085981-B2 | Protein acyl transferase inhibitors and methods of treatment | ACAT2, LCAT, PLAAT2 | ZDHHC9 88/4885L3MBTL1 933/4885MITF 2270/4885 |
| US-20230135119-A1 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | PPT1, SPTLC2, SPTLC1 | ZDHHC9 29/4885L3MBTL1 1123/4885MITF 4601/4885 |
| US-20180200250-A1 | PROTEIN ACYL TRANSFERASE INHIBITORS AND METHODS OF TREATMENT | ACAT2, LCAT, PLAAT2 | ZDHHC9 88/4885L3MBTL1 933/4885MITF 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.